SLCO2B1 and SLCO1B3 as New Targets for Enhancing Androgen Deprivation Therapy for Prostate Cancer

Abstract

We found and validated that the SLCO2B1 exonic SNP rs12422149 was significantly associated with time to progression (TTP) on ADT and that the intronic SNP rs1077858 was associated with overall survival in prostate cancer. The SLCO2B1 exonic SNP rs12422149 significantly impacts the efficiency of the transporter. Individuals or cell lines carrying the major allele of SNP rs1077858 have a significantly lower level of SLCO2B1 expression, compared to those carrying the minor (risk) allele. SLCO2B1 expression levels are directly correlated with DHEAS uptake in prostate cancer cell lines. Additional studies showed that statin use at the time of ADT initiation was associated with a significantly longer TTP on ADT even after adjusting for known clinical prognostic factors. Our in vitro findings that statins competitively reduce DHEAS uptake and thus, effectively decrease the available intratumoral androgen, affords a plausible mechanism to support the clinical observation of prolonged TTP in statin users.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2016
Accession Number
AD1047210

Entities

People

  • Philip W. Kantoff

Organizations

  • Dana–Farber Cancer Institute

Tags

DTIC Thesaurus Topics

  • Androgen Receptors
  • Biomedical Research
  • Cell Line
  • Data Analysis
  • Databases
  • Department Of Defense
  • Endocrine Glands
  • Health Services
  • Information Science
  • Medical Personnel
  • Neoplasms
  • Oncology
  • Polymerase Chain Reaction
  • Prostate Cancer
  • Statins
  • Statistical Analysis
  • Therapy

Fields of Study

  • Chemistry

Readers

  • Molecular Genetics
  • Oncology (Cancer Research).
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.